Hemostatic Powders: A Modern Tool for Gastrointestinal Bleeding

Hemostatic powders represent one of the most interesting developments in endoscopic bleeding management over the past decade. While traditional mechanical and thermal methods remain our mainstays, these powder-based agents offer unique advantages in challenging bleeding scenarios where conventional approaches may fall short.

The Science Behind Hemostatic Powders

The mechanism of action for hemostatic powders is elegantly simple yet highly effective. When applied to a bleeding surface, these agents absorb blood and water, which initiates coagulation and stabilization of the blood clot, leading to temporary bleeding cessation. The concept actually originated from military applications, where the US Army explored using similar powders in battlefield situations to control massive hemorrhage from traumatic amputations.

In the gastrointestinal tract, the powder works through multiple complementary mechanisms. It recruits platelets, traps red blood cells, and creates a controlled inflammatory process involving white blood cells, all of which contribute to forming a stable coagulum. Once applied, the product creates a protective membrane and barrier after water absorption is complete.

The research validating these mechanisms has been particularly thorough. Holster and colleagues from Holland published excellent work in Endoscopy, including electron microscopy studies that beautifully demonstrated how red blood cells and fibrin networks form. Their studies confirmed that hemostatic sprays like Hemospray significantly reduce rebleeding time and accelerate clot formation.

Clinical Application and Technique

Application requires a specialized delivery system consisting of a cartridge that forcefully pumps the powder through either a 7 or 10 French catheter. This catheter size requirement has important practical implications for scope selection and procedural planning.

I've used these agents in challenging cases, such as post-ESD bleeding that continued despite clips, injection, and fibrin application. In one memorable case, we discovered the patient had acquired von Willebrand disease only after the procedure, which explained the refractory bleeding. The hemostatic powder provided the temporary hemostasis we needed.

Clinical Evidence and Effectiveness

The data supporting hemostatic powders is quite compelling for non-variceal bleeding. The study by Lau and colleagues included 224 patients with various causes of GI bleeding, including challenging tumor-related hemorrhages. They found that traditional therapy versus Hemospray showed equivalent efficacy, demonstrating that hemostatic powder was non-inferior for non-variceal upper GI bleeding.

However, it's crucial to understand that most studies show these agents provide efficient initial hemostasis, but long-term hemostasis is not achievable with powders alone. They serve as excellent bridging therapy, allowing time for definitive treatment planning or patient stabilization.

Limitations in Variceal Bleeding

While we'd love to have effective powder therapy for variceal bleeding, the evidence remains unconvincing. A pilot study from Egypt and Belgium attempted to address this question, but several factors make the results difficult to interpret and reproduce in clinical practice.

The study used 10 French catheters, which most practices cannot accommodate without therapeutic gastroscopes. Additionally, patients receiving Hemospray were treated within two hours of presentation, while control patients underwent endoscopy up to 24 hours later. This timing discrepancy makes meaningful comparison impossible.

In my view, hemostatic powder is not a viable option for variceal bleeding, though I commend researchers for tackling this difficult clinical challenge.

Evolution of Hemostatic Agents

Second-generation sprays like Endoclot use the same coagulation mechanism but derive from more biological sources rather than mineral-based compounds like sand. While some countries still use Endoclot, large-scale studies demonstrating superiority are lacking.

More intriguing developments include polyethylene oxide adhesives, which form not just a membrane but create an adhesive bond with the mucosa, potentially lasting longer than traditional powders. A Chinese study of 667 patients undergoing gastric ESD showed reduced bleeding when this agent was used prophylactically, though the retrospective design limits our interpretation.

The most promising advancement may be what I consider third-generation powder technology. UI-EWD (Nexpowder), a biocompatible natural polymer consisting of aldehyde dextran and modified amino acids, transforms into a gel after application. Large Korean studies suggest this powder-to-gel formulation performs as well as conventional therapy while offering unique handling characteristics.

Key Clinical Pearls

• Hemostatic powders excel as bridging therapy for temporary bleeding control, not as definitive treatment
• Non-variceal bleeding responds well to powder therapy, but variceal bleeding remains problematic
• Catheter size requirements (7-10 French) may limit scope selection and procedural flexibility
• These agents work best when combined with traditional hemostatic methods rather than as standalone therapy
• Third-generation powder-to-gel formulations may offer improved durability and effectiveness

Hemostatic powders have earned their place in our therapeutic armamentarium for managing acute GI hemorrhage. While they're not magic bullets, they provide valuable options in challenging bleeding scenarios where traditional approaches may be insufficient.

For a deeper dive into the technical aspects and clinical applications of hemostatic powders, I encourage you to watch the complete video discussion where we explore additional case examples and practical implementation strategies.